- Home
- HFFG vs TVRD Comparison
HFFG vs TVRD Comparison
Compare HFFG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- TVRD
- Stock Information
- Founded
- HFFG 1997
- TVRD 2017
- Country
- HFFG United States
- TVRD United States
- Employees
- HFFG N/A
- TVRD N/A
- Industry
- HFFG Food Distributors
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- HFFG Consumer Discretionary
- TVRD Health Care
- Exchange
- HFFG Nasdaq
- TVRD Nasdaq
- Market Cap
- HFFG 208.3M
- TVRD 246.5M
- IPO Year
- HFFG N/A
- TVRD N/A
- Fundamental
- Price
- HFFG $3.82
- TVRD $29.87
- Analyst Decision
- HFFG
- TVRD Strong Buy
- Analyst Count
- HFFG 0
- TVRD 2
- Target Price
- HFFG N/A
- TVRD $52.00
- AVG Volume (30 Days)
- HFFG 156.2K
- TVRD 48.4K
- Earning Date
- HFFG 05-12-2025
- TVRD 05-13-2025
- Dividend Yield
- HFFG N/A
- TVRD N/A
- EPS Growth
- HFFG N/A
- TVRD N/A
- EPS
- HFFG N/A
- TVRD N/A
- Revenue
- HFFG $1,204,441,000.00
- TVRD N/A
- Revenue This Year
- HFFG $4.77
- TVRD N/A
- Revenue Next Year
- HFFG $3.97
- TVRD N/A
- P/E Ratio
- HFFG N/A
- TVRD N/A
- Revenue Growth
- HFFG 4.71
- TVRD N/A
- 52 Week Low
- HFFG $1.70
- TVRD $8.13
- 52 Week High
- HFFG $4.93
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- HFFG 44.89
- TVRD N/A
- Support Level
- HFFG $3.81
- TVRD N/A
- Resistance Level
- HFFG $4.29
- TVRD N/A
- Average True Range (ATR)
- HFFG 0.21
- TVRD 0.00
- MACD
- HFFG -0.05
- TVRD 0.00
- Stochastic Oscillator
- HFFG 9.68
- TVRD 0.00
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.